APLS — Apellis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.25bn
- $5.30bn
- $1.00bn
Brief: Apellis Pharmaceuticals Q3 Basic EPS USD -0.46
Brief: Apellis Pharmaceuticals Says To Submit Supplemental NDA To FDA In Early 2025
U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks
U.S. RESEARCH ROUNDUP-Cardinal Health, Factset, Paylocity Holding
U.S. STOCKS ON THE MOVE-Visteon, Olo, Arcadium Lithium
Apellis slides as EU panel confirms negative opinion for eye disease drug
U.S. STOCKS ON THE MOVE-Newmont, Nike, Harmony Gold Mining
U.S. STOCKS ON THE MOVE-Constellation Energy, Gold Fields, NovaBay Pharma
U.S. STOCKS ON THE MOVE-Nike, Battalion Oil, gold miners
Brief: EMA'S CHMP Grants Marketing Authorisation For AbbVie's Ovarian Cancer Therapy Elahere
Apellis falls as EU panel confirms negative opinion for eye disease drug
Brief: Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP- Apollo, Blackstone, Hershey
Apellis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Apellis Pharmaceuticals Q2 Basic EPS USD -0.3
Apellis Pharmaceuticals Inc expected to post a loss of 32 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-AT&T, ATI, California Resources
U.S. RESEARCH ROUNDUP-Biontech, Honeywell International, Klaviyo
U.S. RESEARCH ROUNDUP-Deere & Co, Under Armour, Walmart